Randomisierte ein-blind-Studie mit Patienten berichtete Erfahrungen mit sparsamer externer schräger Faszie gegenüber Standard-Leistenorchiektomie (PRESERVE)
The purpose of this study is to evaluate the difference in patient-reported postoperative outcomes between two standard-of-care surgical techniques for radical orchiectomy (inguinal orchiectomy versus external oblique fascia sparing orchiectomy) for treatment of patients with suspected testicular malignancy. The main questions it aims to answer are:
- Does sparing the external oblique fascia during orchiectomy reduce pain after surgery?
- Is there a difference in narcotic consumption after surgery?
- Is there a difference in neuropathic pain after surgery?
- Is there a difference in complications after surgery?
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
Radical inguinal orchiectomy is the standard of care surgical approach for removing a testicle when clinically there is concern for testicular cancer. The procedure is generally minor and performed in the outpatient setting. Recent data demonstrates a trend towards high opioid prescription following this procedure in an attempt to minimize postoperative pain, which is associated with persistent new opioid use in the future. Numerous efforts have been put in place to minimize postoperative pain following scrotal procedures, with success noted when opioid sparing pathways have been adopted. However, there has been sparse data on modifications within surgical technique that could improve patient pain following this procedure.
There have been various descriptions of technique to performing a radical orchiectomy which involves removal of the diseased testicle and spermatic cord. Classically, performing a radical inguinal orchiectomy involves incision of the external oblique fascia to expose and ligate the spermatic cord. During this step, the ilioinguinal nerve is exposed and can be injured by either traction injury or inadvertent transection. Modifications to this technique have been described which involve sparing of the external oblique fascia. Both approaches are performed via a similar incision and both the testicle and spermatic cord are removed. In fascia sparing modification, the spermatic cord is controlled, dissected, and subsequently ligated at the level of the superficial inguinal ring without incising the external oblique fascia. Proponents of this approach suggest the potential for less convalescence and faster recovery due to less tissue manipulation and avoidance of disturbances to the ilioinguinal nerve. Despite this potential benefit, there is no evidence to demonstrate superiority of either approach as it relates to patient recovery.
Therefore, we propose a randomized single-blinded clinical trial investigating postoperative pain outcomes of inguinal radical orchiectomy compared to external oblique fascia sparing radical orchiectomy.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Muhannad Alsyouf, MD
- Telefonnummer: 44196 9095584000
- E-Mail: Malsyouf@llu.edu
Studieren Sie die Kontaktsicherung
- Name: Brian Hu, MD
- Telefonnummer: 44196 9095584000
- E-Mail: Bhu@llu.edu
Studienorte
-
-
California
-
Loma Linda, California, Vereinigte Staaten, 92354
- Rekrutierung
- Loma Linda University
-
Kontakt:
- Muhannad Alsyouf, MD
- Telefonnummer: 44196 9095584000
- E-Mail: Malsyouf@llu.edu
-
Hauptermittler:
- Muhannad Alsyouf, MD
-
Los Angeles, California, Vereinigte Staaten, 90089
- Rekrutierung
- University of Southern California
-
Hauptermittler:
- Siamak Daneshmand
-
Kontakt:
- Siamak Daneshmand, MD
- Telefonnummer: 3238653589
- E-Mail: daneshma@med.usc.edu
-
Unterermittler:
- Hooman Djaladat
-
Unterermittler:
- Anne Schuckman
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Participants undergoing radical orchiectomy for suspected testicular malignancy
- Testicular malignancy can be germ cell tumor or non germ cell tumors, including paratesticular tumors as long as a radical orchiectomy is planned
- Participants over 18 years of age who can provide informed consent
- Participants not currently using opiates for another reason
- Regional and metastatic patients are allowed, as long as participant does not require opiates for pain related to metastatic disease
- No contraindication for participant to receive standardized medication pathway in the peri-operative period.
Exclusion Criteria:
- Clinical T4 disease
- History of illicit substance abuse (including prior opioid abuse) except for marijuana
- Participants who underwent chemotherapy or radiotherapy prior to orchiectomy
- Opioid use within 1 month of study enrollment
- Participants with large testis masses requiring skin incision larger than 8 cm in size.
- Participants with large testis masses requiring orchiectomy through an incision other than the standard transverse inguinal incision (i.e. hockey stick incision, vertical incision)
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Sonstiges
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Aktiver Komparator: Radikale Leistenorchiektomie
|
External oblique fascia will be incised during orchiectomy |
|
Aktiver Komparator: Radikale externe schräge Faszien Sparende Orchiektomie
|
External oblique fascia will be spared during orchiectomy |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Postoperative Pain Level
Zeitfenster: Change between Postoperative day 0 [the day surgery was completed] through postoperative day 7
|
Post-operative pain levels will be measured by the Short Form Inguinal Pain Score (sf-IPQ) The score range is between 0 and 12, with zero points indicating no pain and 12 points indicating the most intense pain. Scores for subjects undergoing inguinal orchiectomy will be compared to subjects undergoing external oblique fascia sparing radical orchiectomy. |
Change between Postoperative day 0 [the day surgery was completed] through postoperative day 7
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Opioid consumption
Zeitfenster: Change between Postoperative day 0 [the day surgery was completed] through postoperative day 7
|
Subjects will self-report the total number of Oxycodone 5 mg tablets consumed for breakthrough pain during the first post-op week. There is no pre-defined range for this self-report but the higher the number of tablets consumed may be an indication of great pain intensity. |
Change between Postoperative day 0 [the day surgery was completed] through postoperative day 7
|
|
Neuropathic Pain Level
Zeitfenster: Change between Postoperative day 0 [the day surgery was completed] through postoperative day 7)
|
Post-Operative Neuropathic pain levels will be measured by the modified Barrow Neurological Institute hypesthesia scale. A total score ranging between 1 and 4, with 1 representing minimal neuropathic pain and 4 representing intense neuropathic pain. |
Change between Postoperative day 0 [the day surgery was completed] through postoperative day 7)
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Urogenitale Erkrankungen
- Genitalerkrankungen
- Schmerzen
- Neurologische Manifestationen
- Erkrankungen des endokrinen Systems
- Postoperative Komplikationen
- Pathologische Prozesse
- Genitale Neubildungen, männlich
- Urogenitale Neoplasmen
- Neubildungen nach Standort
- Neubildungen
- Genitalerkrankungen, männlich
- Männliche Urogenitalerkrankungen
- Neubildungen nach histologischem Typ
- Neoplasmen der endokrinen Drüse
- Gonadenstörungen
- Hodenkrankheiten
- Pathologische Zustände, Anzeichen und Symptome
- Anzeichen und Symptome
- Schmerzen, postoperativ
- Neoplasmen, Keimzelle und Embryonal
- Hodenneoplasmen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 5250002
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .